An "eat me" combinatory nano-formulation for systemic immunotherapy of solid tumors

被引:43
作者
Abdel-Bar, Hend Mohamed [1 ,2 ]
Walters, Adam A. [1 ]
Lim, Yau [1 ]
Rouatbi, Nadia [1 ]
Qin, Yue [1 ]
Gheidari, Fatemeh [1 ]
Han, Shunping [1 ]
Osman, Rihab [3 ]
Wang, Julie Tzu-Wen [1 ]
Al-Jamal, Khuloud T. [1 ]
机构
[1] Kings Coll London, Fac Life Sci & Med, Inst Pharmaceut Sci, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NH, England
[2] Univ Sadat City, Fac Pharm, Dept Pharmaceut, POB 32958, Sadat City, Egypt
[3] Ain Shams Univ, Fac Pharm, POB 11566, Cairo, Egypt
基金
英国惠康基金;
关键词
SNALPs; Immunogenic cell death; doxorubicin; CD47; calreticulin; IMMUNOGENIC CELL-DEATH; BREAST-CANCER; CO-DELIVERY; SIRNA; NANOPARTICLES; DOXORUBICIN; GROWTH; NANOMEDICINE; CALRETICULIN; POTENT;
D O I
10.7150/thno.56936
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Rational: Tumor immunogenic cell death (ICD), induced by certain chemotherapeutic drugs such as doxorubicin (Dox), is a form of apoptosis potentiating a protective immune response. One of the hallmarks of ICD is the translocation of calreticulin to the cell surface acting as an 'eat me' signal. This manuscript describes the development of a stable nucleic acid-lipid particles (SNALPs) formulation for the simultaneous delivery of ICD inducing drug (Dox) with small interfering RNA (siRNA) knocking down CD47 (siCD47), the dominant 'don't eat me' marker, for synergistic enhancement of ICD. Methods: SNALPs loaded with Dox or siCD47 either mono or combinatory platforms were prepared by ethanol injection method. The proposed systems were characterized for particle size, surface charge, entrapment efficiency and in vitro drug release. The ability of the SNALPs to preserve the siRNA integrity in presence of serum and RNAse were assessed over 48 h. The in vitro cellular uptake and gene silencing of the prepared SNALPs was assessed in CT26 cells. The immunological responses of the SNALPs were defined in vitro in terms of surface calreticulin expression and macrophage-mediated phagocytosis induction. In vivo therapeutic studies were performed in CT26 bearing mice where the therapeutic outcomes were expressed as tumor volume, expression of CD4 and CD8 as well as in vivo silencing. Results: The optimized SNALPs had a particle size 122 +/- 6 nm and an entrapment efficiency > 65% for both siRNA and Dox with improved serum stability. SNALPs were able to improve siRNA and Dox uptake in CT26 cells with enhanced cytotoxicity. siCD47 SNALPs were able to knockdown CD47 by approximately 70% with no interference from the presence of Dox. The siCD47 and Dox combination SNALPs were able to induce surface calreticulin expression leading to a synergistic effect on macrophage-mediated phagocytosis of treated cells. In a tumor challenge model, 50% of mice receiving siCD47 and Dox containing SNALPs were able to clear the tumor, while the remaining animals showed significantly lower tumor burden as compared to either monotreatment. Conclusion: Therefore, the combination of siCD47 and Dox in a particulate system showed potent anti-tumor activity which merits further investigation in future clinical studies.
引用
收藏
页码:8738 / 8754
页数:17
相关论文
共 60 条
[1]   A biophysical approach to daunorubicin interaction with model membranes: relevance for the drug's biological activity [J].
Alves, Ana Catarina ;
Ribeiro, Daniela ;
Horta, Miguel ;
Lima, Jose L. F. C. ;
Nunes, Claudia ;
Reis, Salette .
JOURNAL OF THE ROYAL SOCIETY INTERFACE, 2017, 14 (133)
[2]   Influence of doxorubicin on model cell membrane properties: insights from in vitro and in silico studies [J].
Alves, Ana Catarina ;
Magarkar, Aniket ;
Horta, Miguel ;
Lima, Jose L. F. C. ;
Bunker, Alex ;
Nunes, Claudia ;
Reis, Salette .
SCIENTIFIC REPORTS, 2017, 7
[3]   Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat [J].
Amadio, Marialaura ;
Pascale, Alessia ;
Cupri, Sarha ;
Pignatello, Rosario ;
Osera, Cecilia ;
D'Agata, Velia ;
D'Amico, Agata Grazia ;
Leggio, Gian Marco ;
Ruozi, Barbara ;
Govoni, Stefano ;
Dragon, Filippo ;
Bucolo, Claudio .
PHARMACOLOGICAL RESEARCH, 2016, 111 :713-720
[4]   Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma [J].
Aoto, Keita ;
Mimura, Kousaku ;
Okayama, Hirokazu ;
Saito, Motonobu ;
Chida, Shun ;
Noda, Masaru ;
Nakajima, Takahiro ;
Saito, Katsuharu ;
Abe, Noriko ;
Ohki, Shinji ;
Ohtake, Tohru ;
Takenoshita, Seiichi ;
Kono, Koji .
ONCOLOGY REPORTS, 2018, 39 (01) :151-159
[5]   Co-delivery of Doxorubicin and PSC 833 (Valspodar) by Stealth Nanoliposomes for Efficient Overcoming of Multidrug Resistance [J].
Bajelan, Elmira ;
Haeri, Azadeh ;
Vali, Amir Masoud ;
Ostad, Seyed Nasser ;
Dadashzadeh, Simin .
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2012, 15 (04) :568-582
[6]   QuPath: Open source software for digital pathology image analysis [J].
Bankhead, Peter ;
Loughrey, Maurice B. ;
Fernandez, Jose A. ;
Dombrowski, Yvonne ;
Mcart, Darragh G. ;
Dunne, Philip D. ;
McQuaid, Stephen ;
Gray, Ronan T. ;
Murray, Liam J. ;
Coleman, Helen G. ;
James, Jacqueline A. ;
Salto-Tellez, Manuel ;
Hamilton, Peter W. .
SCIENTIFIC REPORTS, 2017, 7
[7]   Doxil® - The first FDA-approved nano-drug: Lessons learned [J].
Barenholz, Yechezkel .
JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134
[8]   A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer [J].
Betancur, Paola A. ;
Abraham, Brian J. ;
Yiu, Ying Y. ;
Willingham, Stephen B. ;
Khameneh, Farnaz ;
Zarnegar, Mark ;
Kuo, Angera H. ;
McKenna, Kelly ;
Kojima, Yoko ;
Leeper, Nicholas J. ;
Ho, Po ;
Gip, Phung ;
Swigut, Tomek ;
Sherwood, Richard I. ;
Clarke, Michael F. ;
Somlo, George ;
Young, Richard A. ;
Weissman, Irving L. .
NATURE COMMUNICATIONS, 2017, 8
[9]   Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47 [J].
Chao, Mark P. ;
Jaiswal, Siddhartha ;
Weissman-Tsukamoto, Rachel ;
Alizadeh, Ash A. ;
Gentles, Andrew J. ;
Volkmer, Jens ;
Weiskopf, Kipp ;
Willingham, Stephen B. ;
Raveh, Tal ;
Park, Christopher Y. ;
Majeti, Ravindra ;
Weissman, Irving L. .
SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (63)
[10]   Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9+ T cells [J].
Chen, Hongmei ;
Cong, Xiuxiu ;
Wu, Chenxi ;
Wu, Xuan ;
Wang, Jialiang ;
Mao, Kuirong ;
Li, Jie ;
Zhu, Ge ;
Liu, Feiqi ;
Meng, Xiandi ;
Song, Jia ;
Sun, Xu ;
Wang, Xin ;
Liu, Shuhan ;
Zhang, Shi ;
Yang, Xianzhu ;
Song, Yanqiu ;
Yang, Yong-Guang ;
Sun, Tianmeng .
SCIENCE ADVANCES, 2020, 6 (05)